Owkin has launched K Navigator, an artificial intelligence (AI)powered research co-pilot designed to revolutionise biomedical science. K Navigator enables users to explore and visualise data, refine questions and uncover insights with ease. It accelerates literature reviews across 26.5 million scientific articles, reveals unexplored and unpublished research areas and delivers more accurate analysis, drawing on 19 biomedical databases featuring thousands of patients. K Navigator is free to academic researchers to strengthen the first AI agentic biomedical collective intelligence. Owkin is working with world-leading institutions to shape and continuously improve it – the next update of the product will include seamless collaboration, result sharing and project organisation, as well as advanced histology tools for filtering, grouping, heat mapping and deeper digital pathology slide analysis.

Central Research Laboratories (CRL) is launching single-use double bags, an addition to its single-use beta bag product line that features a double bag layer for additional protection against contamination in sensitive transfer applications. CRL single-use double bags are engineered to prevent contamination within the ‘ring of concern’, a small area of overlap between a traditional beta bag and the alpha port door that presents a known contamination risk. The double bag consists of an interior and exterior bag, with the interior bag welded to the exterior bag for a secure connection. This design creates a protective layer that enables the highest level of protection against contamination, even in high-speed production. As an added benefit, the double bag acts as a funnel to move items more efficiently. Designed for use in the sterilisation and transfer of high-volume components into isolation during the manufacture of aseptic life sciences products, single-use double Bags are an ideal solution for the hygienic transfer of items such as stoppers, vials and needles.

CRL is launching single-use gamma bags that have been designed to undergo gamma-sterilisation procedures. CRL single-use gamma bags are an addition to the company’s single-use beta bag product line, which also includes the recently launched single-use double bags (see above). Engineers at CRL developed single-use gamma bags in response to requests from life sciences customers who require the use of gamma irradiation rather than steam sterilisation. These bags are constructed of high-density polyethylene for compatibility with gamma-sterilisation processes. They also feature a gray silicon seal that provides easy visual differentiation from CRL Single-Use Beta Bags and Double Bags, which have a black silicon seal. Like all CRL Single-Use Beta Bags, the Gamma Bags provide contamination-free transfer of components into or out of isolation for aseptic manufacturing processes. Made in the US and assembled in an ISO Class 7 cleanroom, Gamma Bags are an ideal solution for the sterilisation and the transfer of items such as syringes, needles, culture media and lab consumables.

Bruker Corporation has announced the new proteoElute nanoLC system, featuring ceramic valves, proteoTrap trapping columns and next-generation PepSep Advanced nLC columns. proteoElute, a state-of-the-art nanoflow liquid chromatography (LC) system designed for robust and ultra-sensitive multiomics applications, is ideal for single-cell proteomics, immunopeptidomics, microbiome metaproteomics profiling and many other proteomics methods, ensuring reliable performance even with limited or very complex biological samples. Engineered for relentless reliability, the proteoElute includes biocompatible ceramic valves, new porous metal filters and a proprietary trap column that together enhance robustness, chromatographic performance and permit sample recovery. For highest sensitivity and performance of the proteoElute nLC system, Bruker introduces a new generation of PepSep Advanced nLC columns, engineered for precision, robustness and speed. Combined with CaptiveSpray Ionisation emitters, users can extend column lifetime by simply replacing the emitter – ensuring long-term performance and cost efficiency. PepSep columns provide the reliability and depth needed for analysing complex tissue digests or low-input samples.

PCI Pharma Services will introduce its new purpose-built facility for large-scale sterile fill-finish operations at its campus in nearby Bedford, New Hampshire, US. With site construction and infrastructure installation now complete, PCI has commenced qualification activities for the Bedford plant’s sophisticated, Annex 1-compliant sterile fill-finish manufacturing technologies. Among other highlights, the facility houses an aseptic vial fill-finish line within a fully isolated containment system, equipped with twin 430sqft lyophilisers featuring automatic loading and unloading systems. As it comes online, the new facility further bolsters PCI’s capacity and capabilities for the sterile fill-finish of late-phase clinical and large-scale commercial small molecule and biologic drugs – including life-changing, high-value drug products such as monoclonal antibodies, fusion proteins and peptides.

CARBOGEN AMCIS is pleased to announce a strategic co-investment of more than ₣25m with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland. The investment will support the production of a drug linker for a commercial antibody-drug conjugate, enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements. This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at Bubendorf, Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth. The new investments will further strengthen the company’s infrastructure to de-liver high-quality manufacturing services in line with current good manufacturing practice and global regulatory expectations.